Volume 6.13 | Apr 7

Hematopoiesis News 6.13 April 7, 2015
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   HN on Twitter
Researchers Develop New Potential Drug for Rare Leukemia
Researchers have developed a new drug candidate that shows potential in laboratory studies against a rare type of acute leukemia. The compound was developed is a small-molecule inhibitor that would block the interaction between the protein menin and MLL fusion proteins that cause a rare type of acute leukemia. [Press release from University of Michigan Medical School discussing online publication in Cancer Cell]
Press Release | Abstract | Graphical Abstract
Enter to Win a Travel Support Award to ISSCR2015!
PUBLICATIONS (Ranked by impact factor of the journal)
Fatal Autoimmunity in Mice Reconstituted with Human Hematopoietic Stem Cells Encoding Defective FOXP3
One obstacle precluding the development of immune-disease specific “humanized” mice is that optimal adaptive immune responses in current strains have required implantation of autologous human thymic tissue. To address this issue, scientists developed a mouse strain that lacks murine major histocompatibility complex class II (MHCII) and instead expresses human MHCII DR1. [Blood] Abstract

Hematopoietic Stem and Progenitor Cells Regulate the Regeneration of Their Niche by Secreting Angiopoietin-1
Researchers systematically assessed the expression and function of Angiopoietin-1 (Angpt1) in bone marrow. Angpt1 was not expressed by osteoblasts. Angpt1 was most highly expressed by hematopoietic stem cells, and at lower levels by c-kit+ hematopoietic progenitors, megakaryocytes, and leptin receptor+ stromal cells. [eLife] Abstract | Full Article

The Tetraspanin CD9 Participates in Dysmegakaryopoiesis and in Stroma Interactions in Primary Myelofibrosis
Scientists investigated whether CD9 participated in the dysmegakaryopoiesis observed in patients and whether it is involved in the altered interplay between megakaryocytes and stromal cells. [Haematologica]
Abstract | Full Article

Conserved and Divergent Aspects of Human T-Cell Development and Migration in Humanized Mice
Investigators compared conventional and non-conventional T-cell development in a neonatal chimera humanized mouse model with that seen in human fetal and neonatal thymus samples, and also examined the impact of a human HLA-A2 transgene expressed by the mouse stroma. They showed that developing human thymocytes engage in short, serial interactions with other human hematopoietic-derived cells. [Immunol Cell Biol] Full Article

BCR/ABL Oncogene-Induced PI3K Signaling Pathway Leads to Chronic Myeloid Leukemia Pathogenesis by Impairing Immuno-Modulatory Function of Hemangioblasts
The authors isolated fetal liver kinase-1-positive cells from chronic myeloid leukemia (CML) patients and found they expressed BCR/ABL-specific CML oncogene. They examined their biological characteristics as well as immunological functions and further detected the possible molecular mechanism involved in the leukemia genesis. [Cancer Gene Ther] Abstract


Subcutaneous versus Intravenous Bortezomib in Two Different Induction Therapies for Newly Diagnosed Multiple Myeloma: Interim Analysis from the Prospective GMMG-MM5 Trial
Researchers investigated impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group that compared bortezomib, doxorubicin, dexamethasone with bortezomib, cyclophosphamide, dexamethasone induction therapy in newly diagnosed multiple myeloma. [Haematologica] Abstract | Full Article

Hematopoietic Stem Cell Transplantation for Refractory Langerhans Cell Histiocytosis: Outcome by Intensity of Conditioning
There are currently two promising treatment strategies for high-risk Langerhans cell histiocytosis (LCH) patients: the first involves the combination of 2-chlorodeoxyadenosine and cytarabine; the other approach is allogeneic hematopoietic stem cell transplantation. Investigators evaluated 87 patients with high-risk LCH who were transplanted between 1990 and 2013. [Br J Haematol] Abstract

Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation
Researchers evaluated the prognostic significance of a modified European LeukemiaNet classification for patients with acute myeloid leukemia undergoing hematopoietic stem cell transplantation while in first complete remission. [Biol Blood Marrow Transplant] Abstract

View Data: StemSpan™ SFEM II Serum-Free Medium
TGF-β Signaling in the Control of Hematopoietic Stem Cells
The authors review key features and emerging concepts pertaining to transforming growth factor-β (TGF-β) and downstream signaling pathways in normal hematopoietic stem cell biology, featuring aspects of aging, hematological disease, and how this circuitry may be exploited for clinical purposes in the future. [Blood] Abstract

β-Thalassemias: Paradigmatic Diseases for Scientific Discoveries and Development of Innovative Therapies
The author summarizes the main discoveries and mechanisms associated with the synthesis of β-globin and abnormal erythropoiesis, as well as current and novel therapies. [Haematologica] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.
MD Anderson, Astellas Pharma Sign Option Agreement
The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc. have signed an option agreement to research and develop a new treatment for patients with acute myeloid leukemia. [The University of Texas MD Anderson Cancer Center] Press Release

Cleveland BioLabs Announces New U.S. Composition of Matter Patent for CBLB612
Cleveland BioLabs, Inc. announced the allowance of a U.S. patent application, to issue as U.S. Patent No. 9,006,183, covering composition of matter for CBLB612, an investigational drug in development for mobilization of hematopoietic stem cells and for the prevention of chemotherapy-induced myelosuppression. [Cleveland BioLabs, Inc.] Press Release

From our sponsor: Working with blood? Download the immune cell frequencies app.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW International Society of Stem Cell Research (ISSCR) 2015 Annual Meeting
June 24-27, 2015
Stockholm, Sweden

Visit our events page to see a complete list of events in the hematopoiesis community.
NEW Postdoctoral Fellow – Hematopoietic Stem Cell Research (Lund University)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Research Fellow – Stem Cell/Hematopoiesis Research (BloodCenter of Wisconsin)

Postdoctoral Fellow – Bioinformatics and Stem Cell Biology (The University of Texas Medical School at Houston)

Research Associate – Hematopoietic and Leukemic Stem Cells (Shanghai Jiao Tong University)

Postdoctoral Research Fellow – Hematopoietic Stem Cell Biology (University of Leuven)

Manufacturing Manager – Cell Therapy (Opexa Therapeutics)

Research Scientist – Cell Signaling in Normal and Leukemic Hematopoietic Stem and Progenitor Cells (Indiana University)

Postdoctoral Position – Drug Development for Anemia (Lund University)

Postdoctoral Position – Pediatric Hematology and Oncology (University Medical Center of Freiburg)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Hematopoiesis News: Archives | Events | Contact Us